News
Minomic and Sienna enter collaboration agreement to develop pancreatic cancer test
Pancreatic cancer is the most lethal cancer in humans, with a 5-year survival rate of less than 10%. There are no liquid biopsy assays for the early detection of pancreatic cancer. There is independent evidence that the protein GPC-1 on exosomes is strongly elevated...
Join us for the 4th global summit on precision diagnosis and treatment of prostate cancer
Keep updated on emerging advances in precision diagnosis in prostate cancer diagnostics and clinical treatment this October in Boston. About the Summit: http://admetech.org
Industry News: Australian Biotech 2030 Vision to emerge from AusBiotech CEO Policy Forum
An Australian Biotechnology 2030 Vision (the Vision) – a decadal framework for the industry – was discussed by Minister Hunt, and supported by Minister Andrews, at the AusBiotech CEO Policy Forum in Canberra last week. Find out more about AusBiotech 2030 Vision
Healthcare Leadership Series: Interview with Brad Walsh
Click here to watch the interview with Brad Walsh, CEO of Minomic International Ltd. The interview is about: - The perspectives on leadership - Best aspects of being involved in the health sector - Important traits a leader should have in the sector - The biggest...
Minomic Signs Agreement with US Pathology Laboratory
Agreement enables early access to the MiCheck® Prostate Cancer Test for US Clinicians & Patients Read Chinese version of the news "Minomic Signs Agreement with US Pathology Laboratory" here February 14, 2019: [Sydney] Minomic International Ltd is pleased to...
Minomic Secures First Prize with MiCheck® at the 2018 Innovation & Entrepreneurship Competition for Overseas High-Level Talents in China
Dr Brad Walsh awarded first prize to boost Minomic’s efforts for MiCheck® China launch - offering a better solution for prostate cancer diagnosis 13 September 2018: [Sydney] Diagnostic company Minomic International Ltd today announced it had secured first prize at the...
Minomic secures key patent in the United States and China
Minomic has received a Notice of Allowance for the company’s patent covering its cell surface antigen for the diagnosis of prostate cancer Sydney, Australia, 5 September 2018: Minomic International Ltd (Minomic), an immuno-oncology company specializing in the...
Minomic completes Prospective Clinical Study using MiCheck® to assist in diagnosis of prostate cancer
58% Fewer patients proceed to Biopsy. US Rollout well advanced. May 17, 2018: [Sydney] Australian immuno-oncology company Minomic International Ltd is pleased to announce the completion of its prospective clinical trial of the company’s novel prostate cancer...
ASCO meeting abstract: Evaluation of the MiCheck MIA test performance in differentiating aggressive from non-aggressive prostate cancer: The MiCheck-01 prospective trial
A poster with headline results of the MiCheck-01 prospective trial was presented by Dr Brad Walsh, Minomic’s CEO at ASCO GU Cancers Symposium 2018 on 8 February. The 350-patient study highlights the test’s performance in differentiating aggressive from non-aggressive...
ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer
A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic's head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary in vitro ADCC assay results revealed the...
Minomic Launches US Prospective Study of MiCheck® Prostate Cancer Test
Novel prostate cancer screening technology targeting commercialization in 2017 Verification of test accuracy and reliability for CLIA lab access July 18, 2017: [Sydney] Minomic International Ltd, an Australian immuno-oncology company, has initiated a prospective US...